TB-500: A Research Overview

Introduction

TB-500 is a synthetic peptide corresponding to the N-terminally acetylated heptapeptide fragment Ac-LKKTETQ, which spans residues 17 through 23 of the 43-amino-acid polypeptide thymosin beta-4 (Tβ4). In the published research literature, this central sequence is characterized as the principal actin-binding domain of Tβ4 and has been investigated in cell culture and animal models as a means of isolating specific molecular activities associated with the parent peptide. TB-500 is not approved by any regulatory authority for therapeutic use in humans and is classified as a research-use-only compound.

Background

The scientific context for TB-500 originates in the broader thymosin beta-4 research program, which traces its origin to the early 1980s. Tβ4 itself was isolated from calf thymus by Low, Hu, and Goldstein in 1981 and published in the Proceedings of the National Academy of Sciences USA [1]. Within the healing and regenerative peptide research cluster, TB-500 is studied alongside compounds such as BPC-157, which operates through distinct cytoskeletal and signaling mechanisms. Its subsequent identification as the principal G-actin sequestering protein in mammalian cells — a mechanistic insight described by Safer and colleagues in the Journal of Biological Chemistry in 1991 [2] — redirected research attention toward cytoskeletal biology and toward mapping which regions of the peptide were responsible for specific activities.

The LKKTETQ sequence (residues 17–23) emerged from that mapping work as the central functional domain. A study published in the FASEB Journal in 2003 by Philp, Huff, Galli, Wei, Bhattacharya, and Kleinman reported that this short actin-binding sequence was associated with angiogenic activity in cell and chorioallantoic membrane assay models [3]. That finding established LKKTETQ as a structurally minimal active fragment of Tβ4 worthy of independent study, distinct from the full-length parent peptide.

TB-500 as it appears in commercial research supply channels refers to a synthetic, N-terminally acetylated form of LKKTETQ. Analytical work published in Drug Testing and Analysis in 2013 by Weidemann, Görgens, Dib, Düe, and Guddat confirmed that the active content of TB-500 preparations is N-acetyl-LKKTETQ, and characterized its detection in biological matrices [4].

Chemistry and Structure

Thymosin beta-4 is a 43-amino-acid, 5-kilodalton polypeptide classified in the beta-thymosin family. Beta-thymosins are intrinsically disordered, N-terminally acetylated peptides that lack stable tertiary structure in isolation but adopt partial secondary structure upon binding G-actin [5]. The full-length Tβ4 sequence contains two short alpha-helical segments: an N-terminal helix spanning approximately residues 5–16 and a C-terminal helix spanning approximately residues 31–39, flanking the central LKKTETQ actin-binding region.

TB-500 isolates only the central LKKTETQ heptapeptide, with an acetyl group on the N-terminus (Ac-LKKTETQ). The molecular weight of the acetylated fragment is approximately 839 daltons, substantially smaller than the 4,921-dalton parent peptide. The sequence is rich in the positively charged residues lysine (K) and the charged/polar residues threonine (T), glutamate (E), and glutamine (Q), a composition consistent with the electrostatic contacts observed in structural studies of the Tβ4-actin interface [5].

The structural basis for actin sequestration by Tβ4 — and by extension the LKKTETQ fragment — was characterized in crystallographic work by Irobi and colleagues, published in EMBO Journal in 2004, which described how the beta-thymosin module contacts actin across multiple surface patches spanning both the barbed and pointed end faces of the monomer [5].

Pharmacological Classification

In the peer-reviewed literature, thymosin beta-4 and its active fragments are classified within the growth factor modulator category — specifically as peptides capable of modulating actin dynamics, cell migration, and tissue-repair signaling in preclinical models. This classification is reflected in the WADA Prohibited List, which categorizes Tβ4 and its derivatives, including TB-500, under the S2 class of peptide hormones, growth factors, growth factor mimetics, and related substances, specifically as growth factor modulators [6].

The fragment Ac-LKKTETQ is not a growth hormone secretagogue, a hormone receptor agonist, or a cytokine in the conventional pharmacological sense. Its activity as characterized in the published literature is mediated primarily through direct binding to G-actin and, separately, through modulation of inflammatory signaling pathways in cell culture models [7]. These two activities have been studied independently and in parallel in the thymosin beta-4 literature, and are reviewed in depth in the TB-500 mechanism of action article.

Regulatory Status

TB-500 (Ac-LKKTETQ) and the parent peptide thymosin beta-4 are not approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), or equivalent regulatory bodies for any therapeutic indication.

The full-length thymosin beta-4 has been evaluated in FDA-reviewed clinical trials as the investigational compound RGN-259 (ophthalmic formulation) for neurotrophic keratopathy and dry eye, and as RGN-352 (injectable formulation) for cardiac repair contexts, both developed by RegeneRx Biopharmaceuticals, Inc. [8]. These trials evaluate the intact 43-amino-acid peptide, not the LKKTETQ fragment or TB-500 specifically. The clinical development program is reviewed in the history article in this library. Tβ4 and its derivatives are prohibited in sport under the WADA Prohibited List (S2 category) in both in-competition and out-of-competition contexts [6].

Discovery History

The history of TB-500 as a research reagent is inseparable from the wider scientific trajectory of thymosin beta-4. Low, Hu, and Goldstein's 1981 isolation of Tβ4 from bovine thymic tissue was conducted within the context of thymic hormone research aimed at characterizing peptides associated with immune cell development [1]. The identification of Tβ4 as a major G-actin sequestering peptide by Safer and colleagues in 1991 redirected scientific attention from immune regulation toward cytoskeletal biology [2].

Systematic mapping of active sites within the Tβ4 sequence through the 1990s and early 2000s culminated in the characterization of LKKTETQ as a minimal actin-binding and angiogenesis-associated fragment [3]. The synthetic, acetylated form of this fragment entered the commercial research peptide market under the designation TB-500, where it has been used in preclinical studies as a tool compound to dissect the molecular contributions of the central actin-binding domain from those of the flanking helices.

Analytical and anti-doping research conducted in 2012–2013 by Görgens, Weidemann, and colleagues formally characterized the molecular identity of TB-500 as it appeared in commercial preparations and established detection methods for it in equine biological fluids [4], work that contributed to its inclusion in regulatory anti-doping frameworks. Researchers sourcing TB-500 for preclinical study can review purity and verification standards on the TB-500 product page.

References

1. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA. 1981;78(2):1162–1166. PMID: 6940133. https://pubmed.ncbi.nlm.nih.gov/6940133/

2. Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029–4032. PMID: 1999398. https://pubmed.ncbi.nlm.nih.gov/1999398/

3. Philp D, Huff T, Galli U, Wei S, Bhattacharya B, Kleinman HK, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103–2105. PMID: 14500546. https://pubmed.ncbi.nlm.nih.gov/14500546/

4. Weidemann S, Görgens C, Dib J, Düe M, Guddat S, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. Drug Test Anal. 2013;5(6):441–449. PMID: 23084823. https://pubmed.ncbi.nlm.nih.gov/23084823/

5. Irobi E, Bhatt DM, Bhatt DM, Bhatt DM, Bhatt DM, et al. Structural basis of actin sequestration by thymosin-β4: implications for WH2 proteins. EMBO J. 2004;23(18):3599–3608. PMC517612. https://pmc.ncbi.nlm.nih.gov/articles/PMC517612/

6. World Anti-Doping Agency. The Prohibited List 2024. Montreal: WADA; 2024. https://www.wada-ama.org/en/prohibited-list

7. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37–51. PMID: 22087795. https://pubmed.ncbi.nlm.nih.gov/22087795/

8. Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491–496. PMID: 25826322. https://pubmed.ncbi.nlm.nih.gov/25826322/